Lipterra (Simvastatin)

Simvastatin is used to manage disorders of lipid metabolism and to lower cardiovascular risk.

• Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels.
• Familial hypercholesterolemia: helps achieve target lipid levels in genetically predisposed patients.
• Prevention of cardiovascular disease: lowers the incidence of myocardial infarction and stroke in at‑risk populations.

• Simvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis. This inhibition decreases intracellular cholesterol, prompting up‑regulation of LDL receptors on hepatocyte surfaces, which enhances clearance of circulating LDL particles and lowers plasma cholesterol concentrations.

Simvastatin may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Muscle aches or weakness: mild myalgia without laboratory abnormalities.
• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
• Headache: transient and usually mild.
• Elevated liver enzymes: asymptomatic transaminase rise.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with potential renal impairment.
• Hepatotoxicity: marked increase in liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or angioedema.
• Myopathy with marked CK elevation: requires immediate medical evaluation.

Before initiating therapy, consider the following safety measures.

• Pregnancy: contraindicated (Category X); avoid use in pregnant women.
• Breastfeeding: not recommended; potential for drug transfer to infant.
• Liver disease: assess hepatic function; avoid if active liver disease is present.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Renal impairment: monitor renal function, especially in severe cases.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Simvastatin interacts with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may cause dangerous increases in simvastatin levels.
• Gemfibrozil: markedly raises risk of myopathy and rhabdomyolysis.
• Danazol: can substantially elevate plasma concentrations.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce absorption, monitor lipid response.
• Warfarin: may enhance anticoagulant effect; check INR regularly.
• Cyclosporine: modest increase in statin exposure; assess for muscle symptoms.
• Grapefruit juice: can increase drug levels; advise limited consumption.